Case Report (n=1)
No
Ivabradine toxicity can cause severe, profound bradycardia and cardiogenic shock that may be refractory to atropine, necessitating aggressive chronotropic support and temporary pacemaker placement.
May require pacing for refractory bradycardia in ivabradine overdose; case report leaves optimal management open.
Ivabradine is a unique antiarrhythmic drug that was designed to affect chronotropy with no effect on inotropy or lusitropy. It was first approved by the European Medicines Agency in 2005 for stable angina treatment, and then in 2009 the indication was expanded to include uncontrolled angina with heart rates ≥60 beats per minute (bpm) on optimal beta-blocker therapy.1 Based on the SHIFT – HF trial in 2011, it got accepted for use in patients with systolic heart failure with heart rate greater than 70 bpm on maximally tolerated beta-blocker therapy or who have contraindication(s) to beta-blockers.
No takes yet. Share an insight, caveat, or question.
Osei et al. (2020) conducted a case report in Ivabradine toxicity (n=1). Ivabradine overdose was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: